Literature DB >> 2529858

UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic.

J C Danilewicz1, P L Barclay, I T Barnish, D Brown, S F Campbell, K James, G M Samuels, N K Terrett, M J Wythes.   

Abstract

A search for potent inhibitors of EC 3.4.24.11, an enzyme which is found most abundantly in the kidney and which degrades atrial natriuretic factor, has led to the identification of UK-69,578. Structure-activity studies starting from substituted N-carboxymethyl dipeptide inhibitors resulted in the introduction of a cyclo-alkane P1' residue and in the replacement of the aza-link between P1 and P1' residues by a methylene group, with a net ten-fold potency gain. UK-69,578 increases endogenous ANF levels and produces natriuretic and diuretic responses intravenously in mice.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529858     DOI: 10.1016/0006-291x(89)91682-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Therapeutic use of atrial natriuretic factor.

Authors:  J M Connell; A G Jardine; D B Northridge
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  Renal effects of concurrent E-24.11 and ACE inhibition in the aorto-venocaval fistula rat.

Authors:  J E Kirk; M R Wilkins
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat.

Authors:  Y Vanneste; S Pauwels; L Lambotte; A Michel; R Dimaline; M Deschodt-Lanckman
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

4.  Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

Authors:  A Plamboeck; J J Holst; R D Carr; C F Deacon
Journal:  Diabetologia       Date:  2005-07-16       Impact factor: 10.122

5.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

Authors:  M C Fournié-Zaluski; W Gonzalez; S Turcaud; I Pham; B P Roques; J B Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat.

Authors:  M R Wilkins; S L Settle; J E Kirk; S A Taylor; K P Moore; R J Unwin
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

7.  Effect of endopeptidase-24.11 inhibition and of atrial natriuretic peptide clearance receptor ligand on the response to rat brain natriuretic peptide in the conscious rat.

Authors:  J E Kirk; M R Wilkins
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 8.  Vasopeptidase inhibitors: will they have a role in clinical practice?

Authors:  Matthew I Worthley; Roberto Corti; Stephen G Worthley
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

9.  Effects of the neutral endopeptidase inhibitor thiorphan on cardiovascular and renal function in cirrhotic rats.

Authors:  K S Park; Y Li; Y Zhang; A L Gerbes; H Liu; M G Swain; S S Lee
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

10.  Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity.

Authors:  T Matsumura; K Kugiyama; S Sugiyama; M Ohgushi; K Amanaka; M Suzuki; H Yasue
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.